Abenex and Cisbio’s management announce the sale of Cisbio Bioassays to PerkinElmer
Aprile 2019
Abenex and Cisbio’s management are delighted to announce the acquisition by PerkinElmer from Abenex of Cisbio Bioassays, a leading custom assay service provider with a broad portfolio of Homogeneous Time Resolved Fluorescence (HTRF)® kits and reagents.
Founded in 1974, and headquartered in Codolet, France, Cisbio has more than 200 employees. Cisbio develops, manufactures, and markets high quality kits and reagents for the life sciences and drug discovery markets. After a successful ramp up over the last four years as a standalone company, Cisbio's management and Abenex were looking for the next development step to find a partner which could support Cisbio's ambitious growth plan.
Cisbio’s portfolio will expand PerkinElmer’s current offerings for life sciences researchers. Specifically, Cisbio’s market leading and proprietary HTRF screening technology will ideally complement PerkinElmer’s customers’ upstream workflows such as target identification and characterization, along with downstream applications such as lead optimization and validation.
"This operation represents a promising match for our company,“ declared Joseph Jammal, CEO of Cisbio. "This will enable us to serve even better the scientific community with a best-in-class reagent and custom assay offer based on no-wash detection assays."
